| Expression pattern: |
DN |
| Associated gene: |
PTBP1, TRIP12, Vimentin, PARP1, HMGA1, PKM1, PKM2, E-cadherin |
| Associated microRNA: |
- |
| Biological function: |
Inhibits NSCLC progression and metastasis, suppresses proliferation, migration and invasion, and blocks aerobic glycolysis. |
| Molecular mechanism: |
Acts as a scaffold binding PTBP1 and TRIP12 to promote TRIP12-mediated PTBP1 polyubiquitylation and proteasomal degradation, thereby reducing PKM2 and Vimentin and increasing PKM1 and E-cadherin. |
| Biological pathway or process: |
glycolysis (inhibits); EMT (inhibits); proliferation (inhibits); migration (inhibits); invasion (inhibits); ubiquitination (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; ROC Analysis; RNA Pull-Down; circRIP; RIP (RNA Immunoprecipitation); Co-IP; Transfection; CCK8; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot |
| Clinical significance: |
Downregulation of circEPB41L2 was relevant to unfavourable outcomes in NSCLC patients and showed diagnostic potential (AUC=0.75). |
| Description: |
circEPB41L2 is down-regulated in NSCLC and acts as a tumor suppressor. It serves as a scaffold to recruit TRIP12 to PTBP1, promoting PTBP1 ubiquitination and proteasomal degradation, thereby inhibiting aerobic glycolysis and EMT and reducing NSCLC growth and metastasis. |
| Confidence score: |
0.8872 |